Objectives: The protozoan parasite Giardia lamblia causes the intestinal disease giardiasis, which may lead to acute and chronic diarrhoea in humans and various animal species. For treatment of this disease, several drugs such as the benzimidazole albendazole, the nitroimidazole metronidazole and the nitrothiazolide nitazoxanide are currently in use. Previously, a G. lamblia nitroreductase 1 (GlNR1) was identified as a nitazoxanide-binding protein. The aim of the present project was to elucidate the role of this enzyme in the mode of action of the nitro drugs nitazoxanide and metronidazole.
Introduction
Giardia lamblia (syn. Giardia duodenalis; Giardia intestinalis), a flagellated protozoan, is the most common causative agent of persistent diarrhoea worldwide. 1 For antigiardial chemotherapy only a few effective drugs are available, namely the nitroheterocyclic drugs tinidazole, metronidazole, furazolidone, the substituted acridine quinacrine, the aminoglycoside paromomycin and the benzimidazole albendazole. 2 -4 In 2000, the nitrothiazolide nitazoxanide was introduced as an alternative option. 5, 6 Concerning the mode of action of metronidazole and related drugs with nitro groups, the current evidence suggests that the nitro group is reduced to a toxic nitro radical via a redox mechanism involving the pyruvate:ferredoxin oxidoreductase (PFOR) system 3, 7 or other enzymes such as nitroreductases. 8 However, it is not clear how nitazoxanide exerts its antiparasitic activity. Nitazoxanide inhibits recombinant bacterial PFORs by a mechanism involving the abstraction of a proton from the thiamine pyrophosphate vitamin co-factor of PFOR through the nitazoxanide anion, thereby inhibiting the production of acetyl-coenzyme A and CO 2 necessary for energy metabolism. 9, 10 According to this model, nitazoxanide would display its antimicrobial activity without the involvement of nitro reduction. 10 We have previously identified a nitroreductase from G. lamblia (GlNR1) as a nitazoxanide-binding protein. The activity of recombinant GlNR1 on dinitrotoluene was inhibited in vitro by nitazoxanide. However, reduction of nitazoxanide or metronidazole in vitro could not be detected. 11 In another study, we found that a nitazoxanide-resistant clone of G. lamblia WBC6 exhibited significantly lower GlNR1 mRNA levels compared with the wild-type WBC6. 12 These findings suggested the following three hypotheses for the involvement of GlNR1 in the mode of action of nitazoxanide: (i) GlNR1 activates nitazoxanide by partial reduction, yielding a toxic radical or a nitroso or hydroxylamine intermediate that could be even more relevant for toxicity than the radical; 13 (ii) GlNR1 inactivates nitazoxanide by full reduction, yielding the corresponding amine, which is inactive; 14 (iii) independently of the reduction of xenobiotics, GlNR1 has an essential function in an unknown metabolic pathway that is inhibited via the binding of nitro drugs.
In order to distinguish between these hypotheses, we have chosen a reverse genetics approach, by overexpressing GlNR1 in G. lamblia and Eschericha coli and determined the susceptibilities of the resulting lines to nitazoxanide and metronidazole as compared with control, glucuronidase-transformed recombinant 
Materials and methods

Tissue culture media, biochemicals and drugs
If not otherwise stated, all biochemical reagents were from Sigma (St Louis, MO, USA). Nitazoxanide was synthesized at the Department of Chemistry and Biochemistry, University of Berne (C. Leumann). Nitazoxanide, metronidazole and albendazole were kept as 100 mM stock solutions in DMSO at 2208C.
Axenic culture of Giardia trophozoites
Trophozoites from G. lamblia WB clone C6 were grown under anaerobic conditions in 10 mL culture tubes (Nunc, Roskilde, Denmark) containing modified TYI-S-33 medium. 15 The nitazoxanide-resistant clone C4 12 was grown in the presence of 40 mM nitazoxanide. Twenty-four hours prior to an experiment, C4 trophozoites were transferred to drug-free, modified TYI-S-33 medium. Trophozoites were detached by incubation on ice for 30 min. Suspended motile trophozoites were counted (Neubauer chamber). Subcultures were initiated by adding 2 -20 mL of trophozoites in a new culture tube. Trophozoites were grown to near confluence and harvested by centrifugation (600 g, 15 min, 48C). Trophozoite pellets were washed three times with PBS, pH 7.2, and stored at 2808C.
Overexpression of recombinant GlNR1
Cloning and heterologous expression of GlNR1 and b-glucuronidase A (GusA) in the E. coli His-tag expression vector system pET151 (pET151 directional TOPO; Invitrogen, Carlsbad, CA, USA) were carried out as previously described. 11, 16 Clones with high expression levels of the recombinant proteins 11, 16 were used for the re-cloning of the GlNR1 and the GusA open reading frames into the vector pPacV-Integ (kindly provided by A. Hehl, Institute of Parasitology, Zü rich, Switzerland). Applying the XbaI and PacI sites of the vector for integration, 17 a forward primer was designed starting with the XbaI site followed by the constitutive glutamate dehydrogenase (GDH) promoter. 18 In the reverse primer, a sequence encoding a human influenza haemagglutinin (HA) tag was included 5
′ of the PacI site (Table 1) . PCRs were performed using Pfu polymerase (Promega, Madison, WI, USA), and fragments were cloned into the Zero Blunt TOPO vector (Invitrogen) according to the manufacturer's instructions. Inserts were excised with XbaI and PacI and ligated into pPacV thus yielding pPacV-GlNR1 or pPacV-GusA. Prior to transfection, the vectors were linearized by digestion with SwaI in order to allow chromosomal integration of the transgene by homologous recombination. Then, transfection of G. lamblia WBC6 and selection of stable transfectants containing GusA or GlNR1 integrated into the genome was performed as previously described via resistance to the antibiotic puromycin. 17 
Antibodies and western blotting
Crude rabbit anti-GlNR1 serum was contracted from GenicBio BioTech (Hong Kong, China). The animal had been immunized with a cocktail of two keyhole limpet haemocyanin (KLH)-coupled peptides representing GlNR1 coding sequence (CDS) 10-22 (RKYHPEPLPKEDL-C) and CDS 58-70 (IAKEVSKNPRYSK-C). Antibodies were affinity-purified on recombinant GlNR1 11 as described previously. 19 Mouse monoclonal antibodies directed against a-tubulin of Trypanosoma brucei and exhibiting cross-reactivity to the analogous protein of G. lamblia clone WBC6 was kindly provided by K. Gull (Dunn School of Pathology, University of Oxford, UK).
Total protein from E. coli and G. lamblia lines was separated by SDS-PAGE (10% gels) under reducing conditions. 20 Western blots were prepared by electrophoretically transferring SDS-PAGE-separated proteins onto nitrocellulose, and non-specific binding sites were blocked overnight at 48C in PBS, pH 7.2 containing skimmed milk powder (2%, w/v), Tween 20 (0.1%, v/v). Primary antibodies, namely affinity-purified rabbit anti-GlNR1 and monoclonal mouse anti-a-tubulin were diluted at 1:10 and 1:10 000 in blocking solution, and blots were incubated overnight at 48C on a horizontal shaker. Blots were then washed four times for 5 min in PBS, pH 7.2, containing 0.1% Tween 20 (PBS/Tween). The secondary antibodies, Alexa Fluor 680-conjugated goat anti-rabbit IgG and IRDye 800-conjugated goat anti-mouse IgG (Li-Cor, Lincoln, NE, USA) were diluted 1:5000 in Odyssey blocking solution (Li-Cor), and added to the respective blots. Blots were then incubated for 1 h at room temperature in the dark, followed by two washes with PBS/Tween and two washes with PBS, pH 7.2, prior to scanning in an Odyssey Infrared Imaging System (Li-Cor). All antibodies were stored at 48C in the dark and could be reused several times.
Determination of drug susceptibility in G. lamblia
Cultures with confluent trophozoite layers were incubated on ice for 15 min. Suspended motile trophozoites were counted and identical Nillius et al.
numbers of trophozoites were inoculated into 96-well plates (0.2 mL per well) in the presence of compound or a solvent control (DMSO). The plates were incubated under anaerobic conditions (100% N 2 ) at 378C for 72 h, and living trophozoites were determined by the resazurin (Alamar blue) vitality assay as described previously. 16, 21 The MIC of a compound was the concentration at which viable trophozoites could not be detected anymore.
Determination of drug susceptibility in E. coli Drug susceptibility of recombinant E. coli BL21(D3) lines expressing either GlNR1 or GusA was tested by a conventional disc-diffusion agar procedure. 22 -24 For this purpose, bacteria were grown to stationary phase (OD 600 ¼1) in Luria-Bertani (LB) medium containing 100 mg/mL ampicillin, and 0.3 mL of suspension was streaked on LB agar plates containing 100 mg/mL ampicillin. Whatman filter discs (5 mm diameter) were soaked with 7 mL of nitazoxanide or metronidazole stock solution (100 mM). Albendazole (100 mM) and kanamycin (2 mM) were included as negative and positive controls, respectively. The discs were air-dried for 5 min and placed on the plates. The plates were incubated under aerobic or microaerobic (5% O 2 /10% CO 2 /85% N 2 ) conditions at 378C for 24 h. Then, growth inhibition zone diameters were measured and the inhibition zone around the disc was calculated (in mm 2 ).
RNA analysis and quantification of expression by real-time RT-PCR
For quantification of GlNR1 expression by real-time RT-PCR, trophozoites were grown until confluence as described above. Cells were harvested as described above, and RNA was extracted using a Qiagen RNeasy Kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions. RNA was eluted with RNase-free water and stored at 2808C. First-strand cDNA was synthesized using a Qiagen OmniscriptRT Kit (Qiagen). After quantitative RT-PCR, expression levels were given as relative values in arbitrary units relative to the amount of actin. The primers NRquantF and NRquantR (Table 1) were used for the quantification of endogenous GlNR1 expression, forming a PCR product of coding sequence 526-794 plus 8 nt of the untranslated region. 12 The primers NRquantF and HATagR (Table 1) were used for the quantification of exogenous GlNR1 expression. The primers ACTquantF and ACTquantR (Table 1) were used for the quantification of a constitutively expressed gene, namely the G. lamblia actin transcript. 12 Quantitative RT-PCR was carried out on a LightCycler TM Instrument (Roche Diagnostics, Rotkreuz, Switzerland) using SYBR Green (Qiagen) as a double-stranded DNA-specific fluorescent dye and continuous fluorescence monitoring as described previously. 25 All PCRs were performed in triplicate. PCR was started by initiating the 'Hot-Start' Taq DNA polymerase reaction at 958C (15 min). Subsequent DNA amplification was carried out in 40 cycles including denaturation (948C, 15 s), annealing (608C, 30 s) and extension (728C, 30 s); temperature transition rates in all cycle steps were 208C/s. Fluorescence was measured at 828C during the temperature shift after each annealing phase in the 'single' mode. Fluorescence signals from the amplification products were quantitatively assessed by applying the standard software (version 3.5.3) of the LightCycler Instrument. Quantification of PCR products was performed during the log phase of the reaction and was achieved by using the secondary derivative maximum mode for plotting of the fluorescence signals versus the cycle numbers. Respective mean values from triplicate determinations were taken for the calculation. From the quantitative RT-PCR, mean values (+SEM) from triplicate determinations were assessed and expression levels of the GlNR1 gene were given as values in arbitrary units relative to the amount of constitutively expressed 'housekeeping' gene actin.
Statistical methods
For statistical analysis of the results from the drug treatment assays with G. lamblia and E. coli and from the determination of GlNR1 expression levels, the Student's t-test in the GraphPad Prism 5 program (GraphPad Software, San Diego, CA, USA) was applied. Differences exhibiting P values of ,0.05 or ,0.001 were considered significant or highly significant, respectively. IC 50 values were calculated as described previously. 16 
Results
Expression of recombinant GlNR1 in G. lamblia strain WBC6
In order to elucidate the importance of nitroreductase for susceptibility to nitro drugs, G. lamblia WBC6 was transfected with either GlNR1 or GusA as a control, both under control of a constitutive promoter. After selection of stable transformants, the mRNA levels of recombinant GlNR1 were determined by quantitative RT-PCRs specific for endogenous and recombinant GlNR1. The corresponding protein expression levels were assessed by western blotting. Endogenous GlNR1 mRNA levels were unchanged in WBC6-GlNR1 as compared with WBC6-GusA. mRNA levels of recombinant GlNR1 and endogenous GlNR1 were three times higher than those of endogenous GlNR1 alone. As shown by immunoblot, enhanced expression of GlNR1 was also clearly visible at the protein level (Figure 1a and b).
WBC6-GlNR1 is more susceptible to nitro drugs than WBC6-GusA
WBC6-GlNR1 and WBC6-GusA were grown in the presence of either of the two nitro drugs nitazoxanide and metronidazole, and albendazole as a control. WBC6-GlNR1 was more susceptible to the two nitro drugs than WBC6-GusA with regard to the corresponding IC 50 values (Table 2 ) and particularly at concentrations between 1.56 and 6.25 mM metronidazole and 3.13 mM nitazoxanide. These values have asterisks in the figure. In contrast, albendazole inhibited growth of both lines identically (Figure 2 ).
E. coli expressing recombinant GlNR1 exhibit increased susceptibility to nitazoxanide under semi-aerobic growth conditions
The previous results suggested that GlNR1 activated rather than inactivated nitro drugs, and thus increased their efficacy. It could, however, not be ruled out that this effect was due to unknown functions of nitroreductases in metabolic pathways specific to Giardia.
To test whether the effect observed above in Giardia could be repeated in a completely different cellular environment, we generated recombinant E. coli lines producing either GlNR1 or heterologous control enzyme GusA. In order to verify the expression of the recombinant proteins, immunoblot analyses of E. coli transformed with GlNR1 and GusA were performed. E. coli transformed with GlNR1 produced the recombinant protein even under non-induced conditions. Cross-reaction of the anti-GlNR1 antibody with endogenous E. coli proteins was not observed (Figure 3a) . Since overproduction of both GlNR1 and control protein GusA in IPTG-induced E. coli strongly Nitroreductase and nitro drugs in G. lamblia reduced growth, non-induced, recombinant E. coli cultures were chosen for growth inhibition assays under aerobic and semiaerobic growth conditions.
Under aerobic as well as semi-aerobic growth conditions, nitazoxanide did not affect growth of control bacteria. Under semiaerobic conditions, bacteria expressing GlNR1 were significantly more susceptible to nitazoxanide than control bacteria. However, under aerobic conditions, nitazoxanide had no inhibitory effect (Figure 3b) . Interestingly, metronidazole inhibited growth of control or of GlNR1-transformed bacteria even under aerobic conditions. Bacteria expressing GlNR1 exhibited a slightly more pronounced inhibition under semi-aerobic conditions (Figure 3b ). Kanamycin inhibited both transformed lines similarly with inhibition zones of 150 mm 2 in both cases. Albendazole did not affect growth in either line. No significant differences in Table 2 . IC 50 values of the drug susceptibility assays presented in Figure 2 Drug Figure 2 . Drug susceptibility of G. lamblia WBC6 expressing E. coli GusA and G. lamblia nitroreductase (GlNR1). 96-well plates were inoculated with 2×10
2 GusA or GlNR1 trophozoites per well and grown in the presence of nitazoxanide (a), metronidazole (b) or albendazole (c) at various concentrations. After 72 h, growth of cells was monitored by a vitality assay based on the reduction of resazurin (Alamar blue) to a pink product that was assayed fluorimetrically. Mean values of the relative fluorescence units normalized to the control values (+SEM) are given for four replicates. Asterisks indicate significant differences between GusA and GlNR1 trophozoites (paired t-test, two-sided, P, 0.05).
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susceptibility to nitro drugs between the two recombinant E. coli lines were detected when they were grown aerobically.
Nitazoxanide-resistant Giardia have lower GlNR1 expression levels
As shown above, overexpression of GlNR1 is correlated with a higher susceptibility to nitro drugs. Unfortunately, we could not show the opposite, i.e. a lower susceptibility in nitroreductasesilenced cells since expression of antisense constructs under the same conditions as described above were lethal in our hands, and trophozoites expressing a GlNR1-antisense construct under a weaker promoter were so severely impaired in growth that drug susceptibility assays could not be performed (data not shown). Therefore, we induced resistance to nitazoxanide in WBC6 as described earlier for the previously characterized line derived from clone C4 12 and obtained a nitazoxanideresistant line (NTZII) independently of clone C4. MIC values for both lines were .100 mM as compared with 25 mM for the wildtype. The relative mRNA levels of GlNR1 in clone C4 were .4.9 times lower than in WBC6, and also significantly lower than in line NTZII (Figure 4a) . The lower expression of GlNR1 in nitazoxanide-resistant lines was also shown to occur at the protein level (Figure 4b ).
Discussion
Metronidazole and other antiparasitic nitro drugs are considered to be prodrugs, which are activated by partial reduction forming a toxic radical 26 or a partially reduced nitroso or hydroxylamine intermediate. 13 On the other hand, complete reduction detoxifies nitro compounds, and thus allows some bacteria to use highly toxic compounds such as trinitrotoluene as carbon sources. 27 Overexpression of target enzymes yielding toxic radicals would then correlate with higher susceptibility, while overexpression of target enzymes performing total reduction would result in increased resistance. Our results Lines were plated, discs containing the drugs were added as described and plates were incubated under aerobic or semi-aerobic (5% O 2 /10% CO 2 /85% N 2 ) conditions. After 24 h, diameters of inhibition zones were determined and surface areas of inhibition zones were calculated. Means+SEM are given for three replicates. Three asterisks indicate that values were different at a highly significant level (paired t-test, one-sided, P, 0.001). This figure appears in colour in the online version of JAC and in black and white in the print version of JAC. Nitroreductase and nitro drugs in G. lamblia presented above suggest that in Giardia, the nitroreductase GlNR1 is one of the enzymes with the ability to perform partial reduction of nitro compounds: overexpression of GlNR1 in G. lamblia is followed by higher susceptibility to both metronidazole and nitazoxanide. Interestingly, GlNR1 has a ferredoxin domain, which nicely corroborates the findings about the involvement of ferredoxin as an electron donor for the reduction of metronidazole and other nitro compounds in Giardia. Recent findings have shown that PFOR is not the only possible electron donor for this reduction. 28 Our findings suggest that GlNR1 is another donor, thus explaining resistance formation without involvement of the PFOR system. However, since trophozoites transformed with antisense constructs are not viable, it cannot be ruled out that GlNR1 carries out some still unknown, but essential, functional activities in the intermediate metabolism of Giardia. Therefore, the results obtained with E. coli are of particular interest since they indicate that GlNR1 works in a different cellular environment in the same way as in Giardia (at least with respect to nitro drugs). Moreover, since E. coli grow well under aerobic as well as under semiaerobic conditions, it is possible to explore the effects of these conditions on GlNR1. E. coli that express GlNR1 are susceptible to nitazoxanide under semi-aerobic conditions, but not under aerobic conditions. This corroborates our previous findings that recombinant GlNR1 does not reduce nitazoxanide in vitro under aerobic conditions. 11 The situation is quite different in the presence of metronidazole. Under both aerobic and semi-aerobic conditions, the two E. coli lines are clearly susceptible to metronidazole, with only slight enhancement in E. coli expressing GlNR1. This indicates that in E. coli reduction of metronidazole, but not of nitazoxanide, may be due to endogenous E. coli nitroreductases expressed even under aerobic growth conditions, thus by metabolic pathways different from PFOR or GlNR1-homologous nitroreductases, since both systems are absent from the E. coli genome. In this context it is noteworthy to mention that most of the literature on the antibacterial effects of metronidazole and related nitro drugs concern anaerobic or semi-aerobic bacteria such as Helicobacter pylori. Since E. coli obviously is susceptible to metronidazole, it represents an ideal model of choice to study this drug. This susceptibility has been reported earlier by other authors. 24 Several nitroreductases have been identified in the E. coli genome. Of these, the Ntr gene is most interesting, since transfection of mammalian tumour cells and expression of Ntr rendered these cells metronidazole sensitive. 29, 30 Another interesting candidate is NfsA, a nitroreductase with a good affinity to nitrofurazones and other nitroaromatic compounds. 31 These results, and the fact that nitazoxanide and metronidazole resistance in G. lamblia correlated with strongly reduced GlNR1 expression, suggested participation of the nitroreductase GlNR1 in activation of nitro drugs. Thus, the expression level of this enzyme clearly represents a key factor for the determination of susceptibility versus resistance to nitro drugs in G. lamblia. However, previous studies on differential gene expression patterns in wild-type and resistant lines have shown that the expression levels of a variety of genes are affected. This indicated that resistance formation takes place on a multigenic rather than a monogenic level. 32 Further studies will be necessary to provide coherent information on the complex pathways that determine the antigiardial activity of nitro compounds.
